A Single Ascending Dose Study of CD101 IV in Healthy Subjects

Completed · Phase 1 · Has a placebo group

Conditions studied: Healthy

In brief

A single ascending dose study to evaluate the safety, tolerability, and pharmacokinetics of CD101 IV

Key facts

Study ID

NCT02516904

Run by

Cidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

People needed

32

Starts

2015-07-01

Expected to finish

2015-10-01

Last updated by the study team

2024-05-22

Who can join

Age: 18 and older, up to 55. Sex: any. Healthy volunteers: accepted.

You may qualify if…

• Males surgically sterilized or using contraception,
• No significant findings on physical, ECG, clinical laboratory tests,
• BMI between 18.5 - 32.0,
• Must provide informed consent

You may not qualify if…

• Females of child bearing potential,
• Signs and or symptoms of an acute or chronic illness,
• Use of prescription medications within 28 days,
• Use of OTC, supplements, and herbals within 14 days,
• Current smoker
• Previous participation in a clinical study within 28 days

Where it is running

• Celerion Inc — Tempe, Arizona, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.